Truist Lifts Doximity Target to $24 and Stays on Hold
Truist Securities raised its Doximity (NYSE:DOCS) price target to $24 from $19 and kept a Hold rating after the stock rose 0.46% premarket. Truist projects fiscal 2027 revenue of $673M and adjusted EBITDA of $320M, and fiscal 2028 revenue of $716M and adjusted EBITDA of $347M. Doximity reported Q1 FY27 revenue of $156.6M vs $151.7M expected and slightly missed EPS.
How this was made
The 30-second read
Why it matters
The primary tradable element is the analyst’s price target lift and forecast changes, which can influence short-term positioning, but it is not a fresh earnings or guidance print from Doximity itself in the text provided.
Market read
A sell-side target increase to $24 from $19, plus forecast revisions, may provide near-term support for DOCS but likely does not change the fundamental risk profile by itself.
What to watch
The article notes EBITDA trimming in FY27 despite revenue growth, which could temper enthusiasm if margins do not improve as expected.
Background
Doximity is a digital platform for US medical professionals; the article frames the move around Truist’s revised valuation approach and forecast updates.
Ticker impact
Truist raised Doximity’s price target to $24 from $19 and reiterated Hold, alongside updated FY27 and FY28 revenue and EBITDA assumptions.
Likely modest support for DOCS around the $24 area, with upside dependent on follow-through to the raised revenue outlook.
The newest concrete facts are Truist’s target change and forecast tweaks, while the company’s own guidance update is referenced only generally as “raised its full-year outlook” without new quantified details in this text.
Market effects
Limited read-through to broader healthcare IT, since this is a single-name analyst target change.
None indicated.
None indicated.
Counterpoint
Because the stock is already trading around the new $24 target, the incremental upside from the upgrade may be capped unless new company fundamentals emerge.
Key entities
- companyDoximity
Subject of the article, with Truist raising its price target and reiterating Hold.
- analyst_firmTruist Securities
Raised Doximity’s target to $24 from $19 and updated FY27/FY28 revenue and EBITDA assumptions.
- analyst_firmWells Fargo
Cut the stock to Underweight with an $18 target on August 10, cited as recent competing sell-side view.
